Pharma & Healthcare
Global Human Vaccine Market Research Report 2026
- Mar 14, 26
- ID: 731954
- Pages: 141
- Figures: 145
- Views: 7
This report delivers a comprehensive overview of the global Human Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Human Vaccine. The Human Vaccine market size, estimates, and forecasts are provided in terms of sales volume (M Doses) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Human Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Human Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
CNBG
Changsheng Life
Zhifei
ChengDa Bio
Kangtai
SINOVAC BIOTECH
Hissen
Walvax Biotechnology
GSK
SANOFI
Rong An
NuoCheng Bio
Hualan Bio
Tiantan biological
Changchun Baike
Adimmune
Zhongyianke Biotech
Bharat Biotech
Bavarian Nordic
Sanofi-Pasteur
Indian Immunologicals
KANGH
Henan Grand Biopharma
ZhongKe Biopharm
Zhuoyi Biological
Segment by Type
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, Tetanus
Pneumococcal
Rota vaccine
by Application
Adults
Children
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Human Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Human Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Human Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Human Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
CNBG
Changsheng Life
Zhifei
ChengDa Bio
Kangtai
SINOVAC BIOTECH
Hissen
Walvax Biotechnology
GSK
SANOFI
Rong An
NuoCheng Bio
Hualan Bio
Tiantan biological
Changchun Baike
Adimmune
Zhongyianke Biotech
Bharat Biotech
Bavarian Nordic
Sanofi-Pasteur
Indian Immunologicals
KANGH
Henan Grand Biopharma
ZhongKe Biopharm
Zhuoyi Biological
Segment by Type
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, Tetanus
Pneumococcal
Rota vaccine
by Application
Adults
Children
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Human Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Human Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Human Vaccine Market Overview
1.1 Product Definition
1.2 Human Vaccine by Type
1.2.1 Global Human Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Varicella
1.2.3 Influenza
1.2.4 Polio
1.2.5 Hepatitis A
1.2.6 Rabies
1.2.7 BCG
1.2.8 Hepatitis B
1.2.9 Pertussis, Diphtheria, Tetanus
1.2.10 Pneumococcal
1.3 Human Vaccine by Application
1.3.1 Global Human Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Adults
1.3.3 Children
1.4 Global Human Vaccine Market Size Estimates and Forecasts
1.4.1 Global Human Vaccine Revenue 2021–2032
1.4.2 Global Human Vaccine Sales 2021–2032
1.4.3 Global Human Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Human Vaccine Market Competition by Manufacturers
2.1 Global Human Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Human Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Human Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Human Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Human Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Human Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Human Vaccine, Date of Entry into the Industry
2.8 Global Human Vaccine Market Competitive Situation and Trends
2.8.1 Global Human Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Human Vaccine Players Market Share by Revenue
2.8.3 Global Human Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Vaccine Market Scenario by Region
3.1 Global Human Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Human Vaccine Sales by Region: 2021–2032
3.2.1 Global Human Vaccine Sales by Region: 2021–2026
3.2.2 Global Human Vaccine Sales by Region: 2027–2032
3.3 Global Human Vaccine Revenue by Region: 2021–2032
3.3.1 Global Human Vaccine Revenue by Region: 2021–2026
3.3.2 Global Human Vaccine Revenue by Region: 2027–2032
3.4 North America Human Vaccine Market Facts & Figures by Country
3.4.1 North America Human Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Human Vaccine Sales by Country (2021–2032)
3.4.3 North America Human Vaccine Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Vaccine Market Facts & Figures by Country
3.5.1 Europe Human Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Human Vaccine Sales by Country (2021–2032)
3.5.3 Europe Human Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Human Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Human Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Human Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Vaccine Market Facts & Figures by Country
3.7.1 Latin America Human Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Human Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Human Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Human Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Human Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Vaccine Sales by Type (2021–2032)
4.1.1 Global Human Vaccine Sales by Type (2021–2026)
4.1.2 Global Human Vaccine Sales by Type (2027–2032)
4.1.3 Global Human Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Human Vaccine Revenue by Type (2021–2032)
4.2.1 Global Human Vaccine Revenue by Type (2021–2026)
4.2.2 Global Human Vaccine Revenue by Type (2027–2032)
4.2.3 Global Human Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Human Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Human Vaccine Sales by Application (2021–2032)
5.1.1 Global Human Vaccine Sales by Application (2021–2026)
5.1.2 Global Human Vaccine Sales by Application (2027–2032)
5.1.3 Global Human Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Human Vaccine Revenue by Application (2021–2032)
5.2.1 Global Human Vaccine Revenue by Application (2021–2026)
5.2.2 Global Human Vaccine Revenue by Application (2027–2032)
5.2.3 Global Human Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Human Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 CNBG
6.1.1 CNBG Company Information
6.1.2 CNBG Description and Business Overview
6.1.3 CNBG Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 CNBG Human Vaccine Product Portfolio
6.1.5 CNBG Recent Developments/Updates
6.2 Changsheng Life
6.2.1 Changsheng Life Company Information
6.2.2 Changsheng Life Description and Business Overview
6.2.3 Changsheng Life Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Changsheng Life Human Vaccine Product Portfolio
6.2.5 Changsheng Life Recent Developments/Updates
6.3 Zhifei
6.3.1 Zhifei Company Information
6.3.2 Zhifei Description and Business Overview
6.3.3 Zhifei Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Zhifei Human Vaccine Product Portfolio
6.3.5 Zhifei Recent Developments/Updates
6.4 ChengDa Bio
6.4.1 ChengDa Bio Company Information
6.4.2 ChengDa Bio Description and Business Overview
6.4.3 ChengDa Bio Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 ChengDa Bio Human Vaccine Product Portfolio
6.4.5 ChengDa Bio Recent Developments/Updates
6.5 Kangtai
6.5.1 Kangtai Company Information
6.5.2 Kangtai Description and Business Overview
6.5.3 Kangtai Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Kangtai Human Vaccine Product Portfolio
6.5.5 Kangtai Recent Developments/Updates
6.6 SINOVAC BIOTECH
6.6.1 SINOVAC BIOTECH Company Information
6.6.2 SINOVAC BIOTECH Description and Business Overview
6.6.3 SINOVAC BIOTECH Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 SINOVAC BIOTECH Human Vaccine Product Portfolio
6.6.5 SINOVAC BIOTECH Recent Developments/Updates
6.7 Hissen
6.7.1 Hissen Company Information
6.7.2 Hissen Description and Business Overview
6.7.3 Hissen Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Hissen Human Vaccine Product Portfolio
6.7.5 Hissen Recent Developments/Updates
6.8 Walvax Biotechnology
6.8.1 Walvax Biotechnology Company Information
6.8.2 Walvax Biotechnology Description and Business Overview
6.8.3 Walvax Biotechnology Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Walvax Biotechnology Human Vaccine Product Portfolio
6.8.5 Walvax Biotechnology Recent Developments/Updates
6.9 GSK
6.9.1 GSK Company Information
6.9.2 GSK Description and Business Overview
6.9.3 GSK Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 GSK Human Vaccine Product Portfolio
6.9.5 GSK Recent Developments/Updates
6.10 SANOFI
6.10.1 SANOFI Company Information
6.10.2 SANOFI Description and Business Overview
6.10.3 SANOFI Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 SANOFI Human Vaccine Product Portfolio
6.10.5 SANOFI Recent Developments/Updates
6.11 Rong An
6.11.1 Rong An Company Information
6.11.2 Rong An Description and Business Overview
6.11.3 Rong An Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Rong An Human Vaccine Product Portfolio
6.11.5 Rong An Recent Developments/Updates
6.12 NuoCheng Bio
6.12.1 NuoCheng Bio Company Information
6.12.2 NuoCheng Bio Description and Business Overview
6.12.3 NuoCheng Bio Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 NuoCheng Bio Human Vaccine Product Portfolio
6.12.5 NuoCheng Bio Recent Developments/Updates
6.13 Hualan Bio
6.13.1 Hualan Bio Company Information
6.13.2 Hualan Bio Description and Business Overview
6.13.3 Hualan Bio Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Hualan Bio Human Vaccine Product Portfolio
6.13.5 Hualan Bio Recent Developments/Updates
6.14 Tiantan biological
6.14.1 Tiantan biological Company Information
6.14.2 Tiantan biological Description and Business Overview
6.14.3 Tiantan biological Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Tiantan biological Human Vaccine Product Portfolio
6.14.5 Tiantan biological Recent Developments/Updates
6.15 Changchun Baike
6.15.1 Changchun Baike Company Information
6.15.2 Changchun Baike Description and Business Overview
6.15.3 Changchun Baike Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Changchun Baike Human Vaccine Product Portfolio
6.15.5 Changchun Baike Recent Developments/Updates
6.16 Adimmune
6.16.1 Adimmune Company Information
6.16.2 Adimmune Description and Business Overview
6.16.3 Adimmune Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Adimmune Human Vaccine Product Portfolio
6.16.5 Adimmune Recent Developments/Updates
6.17 Zhongyianke Biotech
6.17.1 Zhongyianke Biotech Company Information
6.17.2 Zhongyianke Biotech Description and Business Overview
6.17.3 Zhongyianke Biotech Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Zhongyianke Biotech Human Vaccine Product Portfolio
6.17.5 Zhongyianke Biotech Recent Developments/Updates
6.18 Bharat Biotech
6.18.1 Bharat Biotech Company Information
6.18.2 Bharat Biotech Description and Business Overview
6.18.3 Bharat Biotech Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Bharat Biotech Human Vaccine Product Portfolio
6.18.5 Bharat Biotech Recent Developments/Updates
6.19 Bavarian Nordic
6.19.1 Bavarian Nordic Company Information
6.19.2 Bavarian Nordic Description and Business Overview
6.19.3 Bavarian Nordic Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Bavarian Nordic Human Vaccine Product Portfolio
6.19.5 Bavarian Nordic Recent Developments/Updates
6.20 Sanofi-Pasteur
6.20.1 Sanofi-Pasteur Company Information
6.20.2 Sanofi-Pasteur Description and Business Overview
6.20.3 Sanofi-Pasteur Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 Sanofi-Pasteur Human Vaccine Product Portfolio
6.20.5 Sanofi-Pasteur Recent Developments/Updates
6.21 Indian Immunologicals
6.21.1 Indian Immunologicals Company Information
6.21.2 Indian Immunologicals Description and Business Overview
6.21.3 Indian Immunologicals Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 Indian Immunologicals Human Vaccine Product Portfolio
6.21.5 Indian Immunologicals Recent Developments/Updates
6.22 KANGH
6.22.1 KANGH Company Information
6.22.2 KANGH Description and Business Overview
6.22.3 KANGH Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.22.4 KANGH Human Vaccine Product Portfolio
6.22.5 KANGH Recent Developments/Updates
6.23 Henan Grand Biopharma
6.23.1 Henan Grand Biopharma Company Information
6.23.2 Henan Grand Biopharma Description and Business Overview
6.23.3 Henan Grand Biopharma Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.23.4 Henan Grand Biopharma Human Vaccine Product Portfolio
6.23.5 Henan Grand Biopharma Recent Developments/Updates
6.24 ZhongKe Biopharm
6.24.1 ZhongKe Biopharm Company Information
6.24.2 ZhongKe Biopharm Description and Business Overview
6.24.3 ZhongKe Biopharm Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.24.4 ZhongKe Biopharm Human Vaccine Product Portfolio
6.24.5 ZhongKe Biopharm Recent Developments/Updates
6.25 Zhuoyi Biological
6.25.1 Zhuoyi Biological Company Information
6.25.2 Zhuoyi Biological Description and Business Overview
6.25.3 Zhuoyi Biological Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.25.4 Zhuoyi Biological Human Vaccine Product Portfolio
6.25.5 Zhuoyi Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Vaccine Industry Chain Analysis
7.2 Human Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Vaccine Production Mode & Process Analysis
7.4 Human Vaccine Sales and Marketing
7.4.1 Human Vaccine Sales Channels
7.4.2 Human Vaccine Distributors
7.5 Human Vaccine Customer Analysis
8 Human Vaccine Market Dynamics
8.1 Human Vaccine Industry Trends
8.2 Human Vaccine Market Drivers
8.3 Human Vaccine Market Challenges
8.4 Human Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Human Vaccine by Type
1.2.1 Global Human Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Varicella
1.2.3 Influenza
1.2.4 Polio
1.2.5 Hepatitis A
1.2.6 Rabies
1.2.7 BCG
1.2.8 Hepatitis B
1.2.9 Pertussis, Diphtheria, Tetanus
1.2.10 Pneumococcal
1.3 Human Vaccine by Application
1.3.1 Global Human Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Adults
1.3.3 Children
1.4 Global Human Vaccine Market Size Estimates and Forecasts
1.4.1 Global Human Vaccine Revenue 2021–2032
1.4.2 Global Human Vaccine Sales 2021–2032
1.4.3 Global Human Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Human Vaccine Market Competition by Manufacturers
2.1 Global Human Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global Human Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Human Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Human Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Human Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Human Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of Human Vaccine, Date of Entry into the Industry
2.8 Global Human Vaccine Market Competitive Situation and Trends
2.8.1 Global Human Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Human Vaccine Players Market Share by Revenue
2.8.3 Global Human Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Human Vaccine Market Scenario by Region
3.1 Global Human Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Human Vaccine Sales by Region: 2021–2032
3.2.1 Global Human Vaccine Sales by Region: 2021–2026
3.2.2 Global Human Vaccine Sales by Region: 2027–2032
3.3 Global Human Vaccine Revenue by Region: 2021–2032
3.3.1 Global Human Vaccine Revenue by Region: 2021–2026
3.3.2 Global Human Vaccine Revenue by Region: 2027–2032
3.4 North America Human Vaccine Market Facts & Figures by Country
3.4.1 North America Human Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Human Vaccine Sales by Country (2021–2032)
3.4.3 North America Human Vaccine Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Vaccine Market Facts & Figures by Country
3.5.1 Europe Human Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Human Vaccine Sales by Country (2021–2032)
3.5.3 Europe Human Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Human Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Human Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific Human Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Vaccine Market Facts & Figures by Country
3.7.1 Latin America Human Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Human Vaccine Sales by Country (2021–2032)
3.7.3 Latin America Human Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Human Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Human Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa Human Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Human Vaccine Sales by Type (2021–2032)
4.1.1 Global Human Vaccine Sales by Type (2021–2026)
4.1.2 Global Human Vaccine Sales by Type (2027–2032)
4.1.3 Global Human Vaccine Sales Market Share by Type (2021–2032)
4.2 Global Human Vaccine Revenue by Type (2021–2032)
4.2.1 Global Human Vaccine Revenue by Type (2021–2026)
4.2.2 Global Human Vaccine Revenue by Type (2027–2032)
4.2.3 Global Human Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global Human Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global Human Vaccine Sales by Application (2021–2032)
5.1.1 Global Human Vaccine Sales by Application (2021–2026)
5.1.2 Global Human Vaccine Sales by Application (2027–2032)
5.1.3 Global Human Vaccine Sales Market Share by Application (2021–2032)
5.2 Global Human Vaccine Revenue by Application (2021–2032)
5.2.1 Global Human Vaccine Revenue by Application (2021–2026)
5.2.2 Global Human Vaccine Revenue by Application (2027–2032)
5.2.3 Global Human Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global Human Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 CNBG
6.1.1 CNBG Company Information
6.1.2 CNBG Description and Business Overview
6.1.3 CNBG Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 CNBG Human Vaccine Product Portfolio
6.1.5 CNBG Recent Developments/Updates
6.2 Changsheng Life
6.2.1 Changsheng Life Company Information
6.2.2 Changsheng Life Description and Business Overview
6.2.3 Changsheng Life Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Changsheng Life Human Vaccine Product Portfolio
6.2.5 Changsheng Life Recent Developments/Updates
6.3 Zhifei
6.3.1 Zhifei Company Information
6.3.2 Zhifei Description and Business Overview
6.3.3 Zhifei Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Zhifei Human Vaccine Product Portfolio
6.3.5 Zhifei Recent Developments/Updates
6.4 ChengDa Bio
6.4.1 ChengDa Bio Company Information
6.4.2 ChengDa Bio Description and Business Overview
6.4.3 ChengDa Bio Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 ChengDa Bio Human Vaccine Product Portfolio
6.4.5 ChengDa Bio Recent Developments/Updates
6.5 Kangtai
6.5.1 Kangtai Company Information
6.5.2 Kangtai Description and Business Overview
6.5.3 Kangtai Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Kangtai Human Vaccine Product Portfolio
6.5.5 Kangtai Recent Developments/Updates
6.6 SINOVAC BIOTECH
6.6.1 SINOVAC BIOTECH Company Information
6.6.2 SINOVAC BIOTECH Description and Business Overview
6.6.3 SINOVAC BIOTECH Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 SINOVAC BIOTECH Human Vaccine Product Portfolio
6.6.5 SINOVAC BIOTECH Recent Developments/Updates
6.7 Hissen
6.7.1 Hissen Company Information
6.7.2 Hissen Description and Business Overview
6.7.3 Hissen Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Hissen Human Vaccine Product Portfolio
6.7.5 Hissen Recent Developments/Updates
6.8 Walvax Biotechnology
6.8.1 Walvax Biotechnology Company Information
6.8.2 Walvax Biotechnology Description and Business Overview
6.8.3 Walvax Biotechnology Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Walvax Biotechnology Human Vaccine Product Portfolio
6.8.5 Walvax Biotechnology Recent Developments/Updates
6.9 GSK
6.9.1 GSK Company Information
6.9.2 GSK Description and Business Overview
6.9.3 GSK Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 GSK Human Vaccine Product Portfolio
6.9.5 GSK Recent Developments/Updates
6.10 SANOFI
6.10.1 SANOFI Company Information
6.10.2 SANOFI Description and Business Overview
6.10.3 SANOFI Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 SANOFI Human Vaccine Product Portfolio
6.10.5 SANOFI Recent Developments/Updates
6.11 Rong An
6.11.1 Rong An Company Information
6.11.2 Rong An Description and Business Overview
6.11.3 Rong An Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Rong An Human Vaccine Product Portfolio
6.11.5 Rong An Recent Developments/Updates
6.12 NuoCheng Bio
6.12.1 NuoCheng Bio Company Information
6.12.2 NuoCheng Bio Description and Business Overview
6.12.3 NuoCheng Bio Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 NuoCheng Bio Human Vaccine Product Portfolio
6.12.5 NuoCheng Bio Recent Developments/Updates
6.13 Hualan Bio
6.13.1 Hualan Bio Company Information
6.13.2 Hualan Bio Description and Business Overview
6.13.3 Hualan Bio Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Hualan Bio Human Vaccine Product Portfolio
6.13.5 Hualan Bio Recent Developments/Updates
6.14 Tiantan biological
6.14.1 Tiantan biological Company Information
6.14.2 Tiantan biological Description and Business Overview
6.14.3 Tiantan biological Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Tiantan biological Human Vaccine Product Portfolio
6.14.5 Tiantan biological Recent Developments/Updates
6.15 Changchun Baike
6.15.1 Changchun Baike Company Information
6.15.2 Changchun Baike Description and Business Overview
6.15.3 Changchun Baike Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Changchun Baike Human Vaccine Product Portfolio
6.15.5 Changchun Baike Recent Developments/Updates
6.16 Adimmune
6.16.1 Adimmune Company Information
6.16.2 Adimmune Description and Business Overview
6.16.3 Adimmune Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Adimmune Human Vaccine Product Portfolio
6.16.5 Adimmune Recent Developments/Updates
6.17 Zhongyianke Biotech
6.17.1 Zhongyianke Biotech Company Information
6.17.2 Zhongyianke Biotech Description and Business Overview
6.17.3 Zhongyianke Biotech Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Zhongyianke Biotech Human Vaccine Product Portfolio
6.17.5 Zhongyianke Biotech Recent Developments/Updates
6.18 Bharat Biotech
6.18.1 Bharat Biotech Company Information
6.18.2 Bharat Biotech Description and Business Overview
6.18.3 Bharat Biotech Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Bharat Biotech Human Vaccine Product Portfolio
6.18.5 Bharat Biotech Recent Developments/Updates
6.19 Bavarian Nordic
6.19.1 Bavarian Nordic Company Information
6.19.2 Bavarian Nordic Description and Business Overview
6.19.3 Bavarian Nordic Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Bavarian Nordic Human Vaccine Product Portfolio
6.19.5 Bavarian Nordic Recent Developments/Updates
6.20 Sanofi-Pasteur
6.20.1 Sanofi-Pasteur Company Information
6.20.2 Sanofi-Pasteur Description and Business Overview
6.20.3 Sanofi-Pasteur Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 Sanofi-Pasteur Human Vaccine Product Portfolio
6.20.5 Sanofi-Pasteur Recent Developments/Updates
6.21 Indian Immunologicals
6.21.1 Indian Immunologicals Company Information
6.21.2 Indian Immunologicals Description and Business Overview
6.21.3 Indian Immunologicals Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 Indian Immunologicals Human Vaccine Product Portfolio
6.21.5 Indian Immunologicals Recent Developments/Updates
6.22 KANGH
6.22.1 KANGH Company Information
6.22.2 KANGH Description and Business Overview
6.22.3 KANGH Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.22.4 KANGH Human Vaccine Product Portfolio
6.22.5 KANGH Recent Developments/Updates
6.23 Henan Grand Biopharma
6.23.1 Henan Grand Biopharma Company Information
6.23.2 Henan Grand Biopharma Description and Business Overview
6.23.3 Henan Grand Biopharma Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.23.4 Henan Grand Biopharma Human Vaccine Product Portfolio
6.23.5 Henan Grand Biopharma Recent Developments/Updates
6.24 ZhongKe Biopharm
6.24.1 ZhongKe Biopharm Company Information
6.24.2 ZhongKe Biopharm Description and Business Overview
6.24.3 ZhongKe Biopharm Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.24.4 ZhongKe Biopharm Human Vaccine Product Portfolio
6.24.5 ZhongKe Biopharm Recent Developments/Updates
6.25 Zhuoyi Biological
6.25.1 Zhuoyi Biological Company Information
6.25.2 Zhuoyi Biological Description and Business Overview
6.25.3 Zhuoyi Biological Human Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.25.4 Zhuoyi Biological Human Vaccine Product Portfolio
6.25.5 Zhuoyi Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Vaccine Industry Chain Analysis
7.2 Human Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Vaccine Production Mode & Process Analysis
7.4 Human Vaccine Sales and Marketing
7.4.1 Human Vaccine Sales Channels
7.4.2 Human Vaccine Distributors
7.5 Human Vaccine Customer Analysis
8 Human Vaccine Market Dynamics
8.1 Human Vaccine Industry Trends
8.2 Human Vaccine Market Drivers
8.3 Human Vaccine Market Challenges
8.4 Human Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Human Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Human Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Human Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Human Vaccine Sales (M Doses) of Key Manufacturers (2021–2026)
Table 5. Global Human Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Human Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Human Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Human Vaccine Average Price (USD/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Human Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Human Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Human Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Human Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Human Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Human Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Human Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Human Vaccine Sales by Region (M Doses), 2021–2026
Table 18. Global Human Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Human Vaccine Sales by Region (M Doses), 2027–2032
Table 20. Global Human Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Human Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Human Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Human Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Human Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Human Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Human Vaccine Sales by Country (M Doses), 2021–2026
Table 27. North America Human Vaccine Sales by Country (M Doses), 2027–2032
Table 28. North America Human Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Human Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Human Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Human Vaccine Sales by Country (M Doses), 2021–2026
Table 32. Europe Human Vaccine Sales by Country (M Doses), 2027–2032
Table 33. Europe Human Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Human Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Human Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Human Vaccine Sales by Region (M Doses), 2021–2026
Table 37. Asia Pacific Human Vaccine Sales by Region (M Doses), 2027–2032
Table 38. Asia Pacific Human Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Human Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Human Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Human Vaccine Sales by Country (M Doses), 2021–2026
Table 42. Latin America Human Vaccine Sales by Country (M Doses), 2027–2032
Table 43. Latin America Human Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Human Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Human Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Human Vaccine Sales by Country (M Doses), 2021–2026
Table 47. Middle East and Africa Human Vaccine Sales by Country (M Doses), 2027–2032
Table 48. Middle East and Africa Human Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Human Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Human Vaccine Sales (M Doses) by Type (2021–2026)
Table 51. Global Human Vaccine Sales (M Doses) by Type (2027–2032)
Table 52. Global Human Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Human Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Human Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Human Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Human Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Human Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Human Vaccine Price (USD/Dose) by Type (2021–2026)
Table 59. Global Human Vaccine Price (USD/Dose) by Type (2027–2032)
Table 60. Global Human Vaccine Sales (M Doses) by Application (2021–2026)
Table 61. Global Human Vaccine Sales (M Doses) by Application (2027–2032)
Table 62. Global Human Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Human Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Human Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Human Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Human Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Human Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Human Vaccine Price (USD/Dose) by Application (2021–2026)
Table 69. Global Human Vaccine Price (USD/Dose) by Application (2027–2032)
Table 70. CNBG Company Information
Table 71. CNBG Description and Business Overview
Table 72. CNBG Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 73. CNBG Human Vaccine Product
Table 74. CNBG Recent Developments/Updates
Table 75. Changsheng Life Company Information
Table 76. Changsheng Life Description and Business Overview
Table 77. Changsheng Life Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 78. Changsheng Life Human Vaccine Product
Table 79. Changsheng Life Recent Developments/Updates
Table 80. Zhifei Company Information
Table 81. Zhifei Description and Business Overview
Table 82. Zhifei Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 83. Zhifei Human Vaccine Product
Table 84. Zhifei Recent Developments/Updates
Table 85. ChengDa Bio Company Information
Table 86. ChengDa Bio Description and Business Overview
Table 87. ChengDa Bio Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 88. ChengDa Bio Human Vaccine Product
Table 89. ChengDa Bio Recent Developments/Updates
Table 90. Kangtai Company Information
Table 91. Kangtai Description and Business Overview
Table 92. Kangtai Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 93. Kangtai Human Vaccine Product
Table 94. Kangtai Recent Developments/Updates
Table 95. SINOVAC BIOTECH Company Information
Table 96. SINOVAC BIOTECH Description and Business Overview
Table 97. SINOVAC BIOTECH Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 98. SINOVAC BIOTECH Human Vaccine Product
Table 99. SINOVAC BIOTECH Recent Developments/Updates
Table 100. Hissen Company Information
Table 101. Hissen Description and Business Overview
Table 102. Hissen Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 103. Hissen Human Vaccine Product
Table 104. Hissen Recent Developments/Updates
Table 105. Walvax Biotechnology Company Information
Table 106. Walvax Biotechnology Description and Business Overview
Table 107. Walvax Biotechnology Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 108. Walvax Biotechnology Human Vaccine Product
Table 109. Walvax Biotechnology Recent Developments/Updates
Table 110. GSK Company Information
Table 111. GSK Description and Business Overview
Table 112. GSK Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 113. GSK Human Vaccine Product
Table 114. GSK Recent Developments/Updates
Table 115. SANOFI Company Information
Table 116. SANOFI Description and Business Overview
Table 117. SANOFI Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 118. SANOFI Human Vaccine Product
Table 119. SANOFI Recent Developments/Updates
Table 120. Rong An Company Information
Table 121. Rong An Description and Business Overview
Table 122. Rong An Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 123. Rong An Human Vaccine Product
Table 124. Rong An Recent Developments/Updates
Table 125. NuoCheng Bio Company Information
Table 126. NuoCheng Bio Description and Business Overview
Table 127. NuoCheng Bio Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 128. NuoCheng Bio Human Vaccine Product
Table 129. NuoCheng Bio Recent Developments/Updates
Table 130. Hualan Bio Company Information
Table 131. Hualan Bio Description and Business Overview
Table 132. Hualan Bio Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 133. Hualan Bio Human Vaccine Product
Table 134. Hualan Bio Recent Developments/Updates
Table 135. Tiantan biological Company Information
Table 136. Tiantan biological Description and Business Overview
Table 137. Tiantan biological Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 138. Tiantan biological Human Vaccine Product
Table 139. Tiantan biological Recent Developments/Updates
Table 140. Changchun Baike Company Information
Table 141. Changchun Baike Description and Business Overview
Table 142. Changchun Baike Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 143. Changchun Baike Human Vaccine Product
Table 144. Changchun Baike Recent Developments/Updates
Table 145. Adimmune Company Information
Table 146. Adimmune Description and Business Overview
Table 147. Adimmune Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 148. Adimmune Human Vaccine Product
Table 149. Adimmune Recent Developments/Updates
Table 150. Zhongyianke Biotech Company Information
Table 151. Zhongyianke Biotech Description and Business Overview
Table 152. Zhongyianke Biotech Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 153. Zhongyianke Biotech Human Vaccine Product
Table 154. Zhongyianke Biotech Recent Developments/Updates
Table 155. Bharat Biotech Company Information
Table 156. Bharat Biotech Description and Business Overview
Table 157. Bharat Biotech Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 158. Bharat Biotech Human Vaccine Product
Table 159. Bharat Biotech Recent Developments/Updates
Table 160. Bavarian Nordic Company Information
Table 161. Bavarian Nordic Description and Business Overview
Table 162. Bavarian Nordic Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 163. Bavarian Nordic Human Vaccine Product
Table 164. Bavarian Nordic Recent Developments/Updates
Table 165. Sanofi-Pasteur Company Information
Table 166. Sanofi-Pasteur Description and Business Overview
Table 167. Sanofi-Pasteur Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 168. Sanofi-Pasteur Human Vaccine Product
Table 169. Sanofi-Pasteur Recent Developments/Updates
Table 170. Indian Immunologicals Company Information
Table 171. Indian Immunologicals Description and Business Overview
Table 172. Indian Immunologicals Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 173. Indian Immunologicals Human Vaccine Product
Table 174. Indian Immunologicals Recent Developments/Updates
Table 175. KANGH Company Information
Table 176. KANGH Description and Business Overview
Table 177. KANGH Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 178. KANGH Human Vaccine Product
Table 179. KANGH Recent Developments/Updates
Table 180. Henan Grand Biopharma Company Information
Table 181. Henan Grand Biopharma Description and Business Overview
Table 182. Henan Grand Biopharma Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 183. Henan Grand Biopharma Human Vaccine Product
Table 184. Henan Grand Biopharma Recent Developments/Updates
Table 185. ZhongKe Biopharm Company Information
Table 186. ZhongKe Biopharm Description and Business Overview
Table 187. ZhongKe Biopharm Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 188. ZhongKe Biopharm Human Vaccine Product
Table 189. ZhongKe Biopharm Recent Developments/Updates
Table 190. Zhuoyi Biological Company Information
Table 191. Zhuoyi Biological Description and Business Overview
Table 192. Zhuoyi Biological Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 193. Zhuoyi Biological Human Vaccine Product
Table 194. Zhuoyi Biological Recent Developments/Updates
Table 195. Key Raw Materials Lists
Table 196. Raw Materials Key Suppliers Lists
Table 197. Human Vaccine Distributors List
Table 198. Human Vaccine Customers List
Table 199. Human Vaccine Market Trends
Table 200. Human Vaccine Market Drivers
Table 201. Human Vaccine Market Challenges
Table 202. Human Vaccine Market Restraints
Table 203. Research Programs/Design for This Report
Table 204. Key Data Information from Secondary Sources
Table 205. Key Data Information from Primary Sources
Table 206. Authors List of This Report
List of Figures
Figure 1. Product Picture of Human Vaccine
Figure 2. Global Human Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Human Vaccine Market Share by Type: 2025 & 2032
Figure 4. Varicella Product Picture
Figure 5. Influenza Product Picture
Figure 6. Polio Product Picture
Figure 7. Hepatitis A Product Picture
Figure 8. Rabies Product Picture
Figure 9. BCG Product Picture
Figure 10. Hepatitis B Product Picture
Figure 11. Pertussis, Diphtheria, Tetanus Product Picture
Figure 12. Pneumococcal Product Picture
Figure 13. Global Human Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 14. Global Human Vaccine Market Share by Application: 2025 & 2032
Figure 15. Adults
Figure 16. Children
Figure 17. Global Human Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Human Vaccine Market Size (US$ Million), 2021–2032
Figure 19. Global Human Vaccine Sales (M Doses), 2021–2032
Figure 20. Global Human Vaccine Average Price (USD/Dose), 2021–2032
Figure 21. Human Vaccine Report Years Considered
Figure 22. Human Vaccine Sales Share by Manufacturers in 2025
Figure 23. Global Human Vaccine Revenue Share by Manufacturers in 2025
Figure 24. Top 5 and Top 10 Global Human Vaccine Players: Market Share by Revenue in Human Vaccine in 2025
Figure 25. Human Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 26. Global Human Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 27. North America Human Vaccine Sales Market Share by Country (2021–2032)
Figure 28. North America Human Vaccine Revenue Market Share by Country (2021–2032)
Figure 29. U.S. Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Canada Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Europe Human Vaccine Sales Market Share by Country (2021–2032)
Figure 32. Europe Human Vaccine Revenue Market Share by Country (2021–2032)
Figure 33. Germany Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. France Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. U.K. Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Italy Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Russia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Asia Pacific Human Vaccine Sales Market Share by Region (2021–2032)
Figure 39. Asia Pacific Human Vaccine Revenue Market Share by Region (2021–2032)
Figure 40. China Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Japan Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. South Korea Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. India Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Australia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Taiwan Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Indonesia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Thailand Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Malaysia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Philippines Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Latin America Human Vaccine Sales Market Share by Country (2021–2032)
Figure 51. Latin America Human Vaccine Revenue Market Share by Country (2021–2032)
Figure 52. Mexico Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Brazil Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Argentina Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Middle East and Africa Human Vaccine Sales Market Share by Country (2021–2032)
Figure 56. Middle East and Africa Human Vaccine Revenue Market Share by Country (2021–2032)
Figure 57. Turkey Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Saudi Arabia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. U.A.E Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Global Sales Market Share of Human Vaccine by Type (2021–2032)
Figure 61. Global Revenue Market Share of Human Vaccine by Type (2021–2032)
Figure 62. Global Human Vaccine Price (USD/Dose) by Type (2021–2032)
Figure 63. Global Sales Market Share of Human Vaccine by Application (2021–2032)
Figure 64. Global Revenue Market Share of Human Vaccine by Application (2021–2032)
Figure 65. Global Human Vaccine Price (USD/Dose) by Application (2021–2032)
Figure 66. Human Vaccine Value Chain
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Table 1. Global Human Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Human Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Human Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global Human Vaccine Sales (M Doses) of Key Manufacturers (2021–2026)
Table 5. Global Human Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Human Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Human Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Human Vaccine Average Price (USD/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Human Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Human Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Human Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of Human Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Human Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Human Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Human Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Human Vaccine Sales by Region (M Doses), 2021–2026
Table 18. Global Human Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global Human Vaccine Sales by Region (M Doses), 2027–2032
Table 20. Global Human Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global Human Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global Human Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global Human Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global Human Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America Human Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Human Vaccine Sales by Country (M Doses), 2021–2026
Table 27. North America Human Vaccine Sales by Country (M Doses), 2027–2032
Table 28. North America Human Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America Human Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Human Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Human Vaccine Sales by Country (M Doses), 2021–2026
Table 32. Europe Human Vaccine Sales by Country (M Doses), 2027–2032
Table 33. Europe Human Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Human Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Human Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Human Vaccine Sales by Region (M Doses), 2021–2026
Table 37. Asia Pacific Human Vaccine Sales by Region (M Doses), 2027–2032
Table 38. Asia Pacific Human Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Human Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Human Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Human Vaccine Sales by Country (M Doses), 2021–2026
Table 42. Latin America Human Vaccine Sales by Country (M Doses), 2027–2032
Table 43. Latin America Human Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Human Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Human Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Human Vaccine Sales by Country (M Doses), 2021–2026
Table 47. Middle East and Africa Human Vaccine Sales by Country (M Doses), 2027–2032
Table 48. Middle East and Africa Human Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Human Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global Human Vaccine Sales (M Doses) by Type (2021–2026)
Table 51. Global Human Vaccine Sales (M Doses) by Type (2027–2032)
Table 52. Global Human Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global Human Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global Human Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Human Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Human Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global Human Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global Human Vaccine Price (USD/Dose) by Type (2021–2026)
Table 59. Global Human Vaccine Price (USD/Dose) by Type (2027–2032)
Table 60. Global Human Vaccine Sales (M Doses) by Application (2021–2026)
Table 61. Global Human Vaccine Sales (M Doses) by Application (2027–2032)
Table 62. Global Human Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global Human Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global Human Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Human Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Human Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global Human Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global Human Vaccine Price (USD/Dose) by Application (2021–2026)
Table 69. Global Human Vaccine Price (USD/Dose) by Application (2027–2032)
Table 70. CNBG Company Information
Table 71. CNBG Description and Business Overview
Table 72. CNBG Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 73. CNBG Human Vaccine Product
Table 74. CNBG Recent Developments/Updates
Table 75. Changsheng Life Company Information
Table 76. Changsheng Life Description and Business Overview
Table 77. Changsheng Life Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 78. Changsheng Life Human Vaccine Product
Table 79. Changsheng Life Recent Developments/Updates
Table 80. Zhifei Company Information
Table 81. Zhifei Description and Business Overview
Table 82. Zhifei Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 83. Zhifei Human Vaccine Product
Table 84. Zhifei Recent Developments/Updates
Table 85. ChengDa Bio Company Information
Table 86. ChengDa Bio Description and Business Overview
Table 87. ChengDa Bio Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 88. ChengDa Bio Human Vaccine Product
Table 89. ChengDa Bio Recent Developments/Updates
Table 90. Kangtai Company Information
Table 91. Kangtai Description and Business Overview
Table 92. Kangtai Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 93. Kangtai Human Vaccine Product
Table 94. Kangtai Recent Developments/Updates
Table 95. SINOVAC BIOTECH Company Information
Table 96. SINOVAC BIOTECH Description and Business Overview
Table 97. SINOVAC BIOTECH Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 98. SINOVAC BIOTECH Human Vaccine Product
Table 99. SINOVAC BIOTECH Recent Developments/Updates
Table 100. Hissen Company Information
Table 101. Hissen Description and Business Overview
Table 102. Hissen Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 103. Hissen Human Vaccine Product
Table 104. Hissen Recent Developments/Updates
Table 105. Walvax Biotechnology Company Information
Table 106. Walvax Biotechnology Description and Business Overview
Table 107. Walvax Biotechnology Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 108. Walvax Biotechnology Human Vaccine Product
Table 109. Walvax Biotechnology Recent Developments/Updates
Table 110. GSK Company Information
Table 111. GSK Description and Business Overview
Table 112. GSK Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 113. GSK Human Vaccine Product
Table 114. GSK Recent Developments/Updates
Table 115. SANOFI Company Information
Table 116. SANOFI Description and Business Overview
Table 117. SANOFI Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 118. SANOFI Human Vaccine Product
Table 119. SANOFI Recent Developments/Updates
Table 120. Rong An Company Information
Table 121. Rong An Description and Business Overview
Table 122. Rong An Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 123. Rong An Human Vaccine Product
Table 124. Rong An Recent Developments/Updates
Table 125. NuoCheng Bio Company Information
Table 126. NuoCheng Bio Description and Business Overview
Table 127. NuoCheng Bio Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 128. NuoCheng Bio Human Vaccine Product
Table 129. NuoCheng Bio Recent Developments/Updates
Table 130. Hualan Bio Company Information
Table 131. Hualan Bio Description and Business Overview
Table 132. Hualan Bio Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 133. Hualan Bio Human Vaccine Product
Table 134. Hualan Bio Recent Developments/Updates
Table 135. Tiantan biological Company Information
Table 136. Tiantan biological Description and Business Overview
Table 137. Tiantan biological Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 138. Tiantan biological Human Vaccine Product
Table 139. Tiantan biological Recent Developments/Updates
Table 140. Changchun Baike Company Information
Table 141. Changchun Baike Description and Business Overview
Table 142. Changchun Baike Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 143. Changchun Baike Human Vaccine Product
Table 144. Changchun Baike Recent Developments/Updates
Table 145. Adimmune Company Information
Table 146. Adimmune Description and Business Overview
Table 147. Adimmune Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 148. Adimmune Human Vaccine Product
Table 149. Adimmune Recent Developments/Updates
Table 150. Zhongyianke Biotech Company Information
Table 151. Zhongyianke Biotech Description and Business Overview
Table 152. Zhongyianke Biotech Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 153. Zhongyianke Biotech Human Vaccine Product
Table 154. Zhongyianke Biotech Recent Developments/Updates
Table 155. Bharat Biotech Company Information
Table 156. Bharat Biotech Description and Business Overview
Table 157. Bharat Biotech Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 158. Bharat Biotech Human Vaccine Product
Table 159. Bharat Biotech Recent Developments/Updates
Table 160. Bavarian Nordic Company Information
Table 161. Bavarian Nordic Description and Business Overview
Table 162. Bavarian Nordic Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 163. Bavarian Nordic Human Vaccine Product
Table 164. Bavarian Nordic Recent Developments/Updates
Table 165. Sanofi-Pasteur Company Information
Table 166. Sanofi-Pasteur Description and Business Overview
Table 167. Sanofi-Pasteur Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 168. Sanofi-Pasteur Human Vaccine Product
Table 169. Sanofi-Pasteur Recent Developments/Updates
Table 170. Indian Immunologicals Company Information
Table 171. Indian Immunologicals Description and Business Overview
Table 172. Indian Immunologicals Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 173. Indian Immunologicals Human Vaccine Product
Table 174. Indian Immunologicals Recent Developments/Updates
Table 175. KANGH Company Information
Table 176. KANGH Description and Business Overview
Table 177. KANGH Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 178. KANGH Human Vaccine Product
Table 179. KANGH Recent Developments/Updates
Table 180. Henan Grand Biopharma Company Information
Table 181. Henan Grand Biopharma Description and Business Overview
Table 182. Henan Grand Biopharma Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 183. Henan Grand Biopharma Human Vaccine Product
Table 184. Henan Grand Biopharma Recent Developments/Updates
Table 185. ZhongKe Biopharm Company Information
Table 186. ZhongKe Biopharm Description and Business Overview
Table 187. ZhongKe Biopharm Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 188. ZhongKe Biopharm Human Vaccine Product
Table 189. ZhongKe Biopharm Recent Developments/Updates
Table 190. Zhuoyi Biological Company Information
Table 191. Zhuoyi Biological Description and Business Overview
Table 192. Zhuoyi Biological Human Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Dose), and Gross Margin (2021–2026)
Table 193. Zhuoyi Biological Human Vaccine Product
Table 194. Zhuoyi Biological Recent Developments/Updates
Table 195. Key Raw Materials Lists
Table 196. Raw Materials Key Suppliers Lists
Table 197. Human Vaccine Distributors List
Table 198. Human Vaccine Customers List
Table 199. Human Vaccine Market Trends
Table 200. Human Vaccine Market Drivers
Table 201. Human Vaccine Market Challenges
Table 202. Human Vaccine Market Restraints
Table 203. Research Programs/Design for This Report
Table 204. Key Data Information from Secondary Sources
Table 205. Key Data Information from Primary Sources
Table 206. Authors List of This Report
List of Figures
Figure 1. Product Picture of Human Vaccine
Figure 2. Global Human Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Human Vaccine Market Share by Type: 2025 & 2032
Figure 4. Varicella Product Picture
Figure 5. Influenza Product Picture
Figure 6. Polio Product Picture
Figure 7. Hepatitis A Product Picture
Figure 8. Rabies Product Picture
Figure 9. BCG Product Picture
Figure 10. Hepatitis B Product Picture
Figure 11. Pertussis, Diphtheria, Tetanus Product Picture
Figure 12. Pneumococcal Product Picture
Figure 13. Global Human Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 14. Global Human Vaccine Market Share by Application: 2025 & 2032
Figure 15. Adults
Figure 16. Children
Figure 17. Global Human Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 18. Global Human Vaccine Market Size (US$ Million), 2021–2032
Figure 19. Global Human Vaccine Sales (M Doses), 2021–2032
Figure 20. Global Human Vaccine Average Price (USD/Dose), 2021–2032
Figure 21. Human Vaccine Report Years Considered
Figure 22. Human Vaccine Sales Share by Manufacturers in 2025
Figure 23. Global Human Vaccine Revenue Share by Manufacturers in 2025
Figure 24. Top 5 and Top 10 Global Human Vaccine Players: Market Share by Revenue in Human Vaccine in 2025
Figure 25. Human Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 26. Global Human Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 27. North America Human Vaccine Sales Market Share by Country (2021–2032)
Figure 28. North America Human Vaccine Revenue Market Share by Country (2021–2032)
Figure 29. U.S. Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Canada Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Europe Human Vaccine Sales Market Share by Country (2021–2032)
Figure 32. Europe Human Vaccine Revenue Market Share by Country (2021–2032)
Figure 33. Germany Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. France Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. U.K. Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Italy Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Russia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Asia Pacific Human Vaccine Sales Market Share by Region (2021–2032)
Figure 39. Asia Pacific Human Vaccine Revenue Market Share by Region (2021–2032)
Figure 40. China Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Japan Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. South Korea Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. India Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Australia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Taiwan Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Indonesia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Thailand Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Malaysia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Philippines Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Latin America Human Vaccine Sales Market Share by Country (2021–2032)
Figure 51. Latin America Human Vaccine Revenue Market Share by Country (2021–2032)
Figure 52. Mexico Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Brazil Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Argentina Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Middle East and Africa Human Vaccine Sales Market Share by Country (2021–2032)
Figure 56. Middle East and Africa Human Vaccine Revenue Market Share by Country (2021–2032)
Figure 57. Turkey Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Saudi Arabia Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. U.A.E Human Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Global Sales Market Share of Human Vaccine by Type (2021–2032)
Figure 61. Global Revenue Market Share of Human Vaccine by Type (2021–2032)
Figure 62. Global Human Vaccine Price (USD/Dose) by Type (2021–2032)
Figure 63. Global Sales Market Share of Human Vaccine by Application (2021–2032)
Figure 64. Global Revenue Market Share of Human Vaccine by Application (2021–2032)
Figure 65. Global Human Vaccine Price (USD/Dose) by Application (2021–2032)
Figure 66. Human Vaccine Value Chain
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232